Recent studies have demonstrated that HDAC 8 can directly interact with EZH2 to repress antagonists specifically targeting oncogenes thus promoting HCC onset and development in NAFLD patients [32]. Here, EZH2 is linked to metabolic dysfunction-associated steatotic liver disease.